Sunitinib for metastatic renal cell carcinoma: Real world data from the STAR-TOR registry and detailed literature review

This study looked at the effectiveness and safety profile of sunitinib, a tyrosine kinase inhibitor, in patients with advanced or metastatic renal cell carcinoma in a real-world setting. Progression-free survival, overall survival, and adverse events in 702 patients were evaluated. The data showed evidence of the relevance of sunitinib for these patients who cannot receive or tolerate immune checkpoint inhibitors.